Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
← Ишга қайтиш

Ушбу иш иқтибос қилган ишлар

194 та иш

Иш: An odyssey of monoclonal gammopathies: focusing on precursors and the progression from MGUS and SMM to multiple Myeloma, with a brief overview of novel therapeutic strategies

  1. The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy

    Shuguang Zhang, Wen‐Ying Chen, Jihong Zhou +5

    Шарҳ мақола20257 иқтибос
    ABI

  2. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25

    Мақола20215 иқтибос
    ABI

  3. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

    S. Vincent Rajkumar

    Мақола20224 иқтибос
    ABI

  4. The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors

    Xiangping Li, Jian Qu, Xin-Qi Teng +4

    Шарҳ мақола20233 иқтибос
    ABI

  5. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani +33

    Мақола20213 иқтибос
    ABI

  6. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

    Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos +80

    Шарҳ мақола20223 иқтибос
    ABI

  7. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

    Larysa Sanchez, Yucai Wang, David S. Siegel +1

    Шарҳ мақола20162 иқтибос
    ABI

  8. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression

    Mark Bustoros, Romanos Sklavenitis‐Pistofidis, Jihye Park +33

    Мақола20202 иқтибос
    ABI

  9. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

    Mattia D’Agostino, David A. Cairns, Juan José Lahuerta +28

    Мақола20222 иқтибос
    ABI

  10. Multiple myeloma

    Florent Malard, Paola Neri, Nizar J. Bahlis +5

    Шарҳ мақола20242 иқтибос
    ABI

  11. Circulating immune cells and risk of osteosarcoma: a Mendelian randomization analysis

    Li Lan, Yeqi Sun, Jia Luo +1

    Мақола20242 иқтибос
    ABI

  12. Plasma cell neoplasms and related entities—evolution in diagnosis and classification

    Falko Fend, Ahmet Doǧan, James R. Cook

    Шарҳ мақола20222 иқтибос
    ABI

  13. Monoclonal Gammopathy of Undetermined Significance

    Wilson I. Gonsalves, S. Vincent Rajkumar

    Шарҳ мақола20222 иқтибос
    ABI

  14. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

    Robert A. Kyle, Ellen D. Remstein, Terry M. Therneau +9

    Мақола20072 иқтибос
    ABI

  15. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Joaquín Martínez‐López, Juan José Lahuerta, François Pépin +21

    Мақола20142 иқтибос
    ABI

  16. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

    S. Vincent Rajkumar, Robert A. Kyle, Terry M. Therneau +7

    Мақола20052 иқтибос
    ABI

  17. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes

    Yinlei Bai, Kwan Yeung Wong, Tsz Kin Fung +1

    Бошқа20162 иқтибос
    ABI

  18. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

    Leo Rasche, Shweta S. Chavan, Owen Stephens +19

    Мақола20172 иқтибос
    ABI

  19. Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

    Alessandro Allegra, Vanessa Innao, Andrea Gaetano Allegra +5

    Шарҳ мақола20192 иқтибос
    ABI

  20. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Elı́as Campo, Elaine S. Jaffe, James R. Cook +70

    Мақола20222 иқтибос
    ABI

  21. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

    Luca Bertamini, Stefania Oliva, Delia Rota‐Scalabrini +26

    Мақола20222 иқтибос
    ABI

  22. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Juan‐José Garcés, María‐Teresa Cedena, Noemí Puig +25

    Мақола20222 иқтибос
    ABI

  23. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma

    Tomáš Jelı́nek, Renata Bezděková, David Žihala +27

    Мақола20222 иқтибос
    ABI

  24. Chromosomal defects in multiple myeloma

    Sarah E. Clarke, Kathryn A. Fuller, Wendy N. Erber

    Шарҳ мақола20242 иқтибос
    ABI

  25. Genomic Classification and Individualized Prognosis in Multiple Myeloma

    Francesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu +34

    Мақола20242 иқтибос
    ABI